Bill Detail
H.Res. 1285
Congress: 119
Title
Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
Summary
No summary published on Congress.gov yet — common for recently introduced bills.
Sponsor
Rep. Diana DeGette [D-CO-1]
Status
Referred to the House Committee on Energy and Commerce.
Status as of Oct 2, 9:16 AM · synced 6h ago
Introduced
2026-05-14
Data source mode: cache
Bill Engagement
Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effect…
Sponsor
Rep. Diana DeGette [D-CO-1]D
Status
Referred to the House Committee on Energy and Commerce.
Cosponsors
54D · 0R
Partisan (D only)
LDA engagement
1 org · 1 filing
Top: Guttmacher Institute
Introduced
2026-05-14
Lobbyists on the case
1 org · 4 lobbyists · 1 filing mention H.Res. 1285 (Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.) in LDA disclosures.
Top orgs filing
- Guttmacher Institute1 filing · 4 lobs
Lobbyists on this bill
- Anna Bernstein2026 Q2Guttmacher Institute · Principal Federal Policy Advisor
- Samira Damavandi2026 Q2Guttmacher Institute · Senior Federal Policy Associate
+ 2 more in the full intelligence view
Prepared intelligence brief
Connect the event to the surrounding activity.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.